AGBL5

Across TCGA pan-cancer cohorts, AGBL5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AGBL5 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AGBL5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AGBL5 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where AGBL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.857	0.499	<.001	38	view →
LUAD	DFS	Median	All	0.985	0.854	.020	10	view →
LSCC	OS	Median	All	0.931	1.000	.010	8	view →
GBM	DFS	Tertile	All	0.672	0.840	.008	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AGBL5–HNSC (OS)

Open the HNSC breakdown →